“A Budget Impact Analysis of the VENTANA PD-L1 SP142 Immunohistochemistry Assay Versus the Dako PD-L1 IHC 22C3 Assay in Patients With Advanced or Metastatic Triple-Negative Breast Cancer Treated With Atezolizumab in Combination With Nab-Paclitaxel” (2021) Farmeconomia. Health economics and therapeutic pathways, 22(1). doi:10.7175/fe.v22i1.1502.